 Postoperative adjuvant chemotherapy non-small cell lung cancer prognostic value DNA ploidy post-recurrent survival Eighty-six patients non-small cell lung cancer curative operations chemotherapy groups adjuvant chemotherapy group patients cisplatin-based combination chemotherapy weeks operation average cycle chemotherapy cycles trial evidence improved survival recurrence treated patients multivariate analysis prognostic variables important factor pathological stage disease second DNA ploidy primary tumor histology squamous non-squamous cell carcinoma trend survival significant factor total patients recurrences patients control adjuvant chemotherapy groups Postrecurrent survival adjuvant chemotherapy group control group generalized Wilcoxon log rank tests Median survival time recurrence control adjuvant therapy groups months results DNA ploidy primary tumors prognostic factor future trials adjuvant therapy Furthermore analysis postrecurrent survival adjuvant chemotherapy trial overall disease-free survivals